| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $299,550 ) |
| | 2024 | 2024 | NEUREXIS THERAPEUTICS, INC. | 12635 E MONTVIEW BLVD | AURORA | CO | 80045-7336 | ADAMS | USA | U44NS132339 | Comparative testing of tatCN19o for neuroprotection in rodent tMCAo | 000 | 2 | NIH | 3/19/2024 | $299,550 |
| | 2024 | 2021 | NEUREXIS THERAPEUTICS, INC. | 12635 E MONTVIEW BLVD | AURORA | CO | 80045-7336 | ADAMS | USA | R43NS120427 | Preparing for IND-enabling safety studies for a potent and efficient neuroprotective drug. | 000 | 1 | NIH | 10/12/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $299,550 ) |
| | 2023 | 2023 | NEUREXIS THERAPEUTICS INC | 12635 E MONTVIEW BLVD | AURORA | CO | 80045-7336 | ADAMS | USA | U44NS132339 | Comparative testing of tatCN19o for neuroprotection in rodent tMCAo | 000 | 1 | NIH | 4/12/2023 | $299,550 |
|
| Issue Date FY: 2021 ( Subtotal = $496,145 ) |
| | 2021 | 2021 | NEUREXIS THERAPEUTICS, INC. | 12635 E MONTVIEW BLVD STE 100 | AURORA | CO | 80045-7336 | ADAMS | USA | R43NS120427 | Preparing for IND-enabling safety studies for a potent and efficient neuroprotective drug. | 000 | 1 | NIH | 9/22/2021 | $496,145 |
|
|
